Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994043 · ClinicalTrials.gov registry record · NA
Alcohol, Inflammation, and Mindfulness Study (AIM)
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT02994043: Completed NA study, sponsored by University of Colorado, Denver.
NCT02994043 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02994043, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.
Primary Outcome
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Interventions
- BEHAVIORAL Relapse Prevention Therapy
- BEHAVIORAL Mindfulness-Based Relapse Prevention Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-11-09 |
| Est. Completion | 2021-02-17 |
| Phase | NA |
What the finished NCT02994043 record still lists
NCT02994043 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Relapse Prevention Therapy is the first listed.
NCT02994043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02994043 about?
NCT02994043 is a clinical study titled "Alcohol, Inflammation, and Mindfulness Study (AIM)". The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteri...
What is the current status of trial NCT02994043?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2016-11-09. Estimated completion is 2021-02-17.
What interventions are being tested in trial NCT02994043?
The interventions under investigation include: Relapse Prevention Therapy (BEHAVIORAL), Mindfulness-Based Relapse Prevention Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02994043?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02994043's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI